Development and licensing agreement for Virtue Sirolimus-Eluting Balloon (SEBDevelopment and Licensing Agreement • July 10th, 2024
Contract Type FiledJuly 10th, 2024Terumo has secured exclusive global development and commercialization rights to Virtue Sirolimus-Eluting Balloon (SEB) for percutaneous coronary interventions by entering into a strategic partnership with Orchestra BioMed.